Molly Gibson
Origination Partner
Molly Gibson is an Origination Partner at Flagship Pioneering, where she leads a Pioneering Business Unit focused on founding, building, and growing companies at the intersection of artificial intelligence and science. She currently serves as CEO and board member of Expedition Medicines.
Molly is an experienced founder, technologist, and builder of AI-native platforms that expand the boundaries of scientific discovery. As Co-Founder and President at Lila Sciences, she led the development of the AI Science Factories, a platform designed to build Scientific Superintelligence by allowing AI to run the scientific method through interaction with a physical lab. As Co-Founder and Chief Strategy & Innovation Officer at Generate: Biomedicines, she helped lead the development of one of the world’s first transformer-based models for protein design — pioneering a new approach to therapeutic creation through generative AI.
At Flagship, Molly also contributed to the launch of Tessera Therapeutics and Cobalt Biomedicines (merged into Sana Biotechnology). Her work has led to numerous patents and peer-reviewed publications in Science and Nature and underpins programs now advancing through clinical development.
A computer scientist by training, she earned her Ph.D. in computational biology at Washington University in St. Louis. Her work has been featured by The New York Times, CNBC, McKinsey & Company, and 60 Minutes, and she was named to Endpoints News' “20 under 40” and Great Entrepreneurs Top 50 BioTech Entrepreneurs.